Liminal BioSciences Inc. PFSCF

Primary Symbol: LMNL

Healthcare Biotechnology

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.

NDAQ:LMNL - Post by User

Liminal BioSciences Inc. > Kedrion option extension announced 2 days late

<< Previous

Bullboard Posts

Next >>

Comment by GunnerGon Jun 17, 2021 8:36pm

59 Views

Post# 33409243

RE:RE:Kedrion option extension announced 2 days late

I got it and yes typical of this companies misdirection. Should have been a NR and where is our $3M for an extension?

GunnerG wrote: great find stockbuphoon. I was waiting for StupsNewcamo to dig a little but of course he is useless.

Under which date in the SEC filings did you find this?

stockbuphoon wrote:
This is just a rookie management team or doing this stuff on purpose which is even more evil.

This Report on Form 6-K (the “Report”) is hereby expressly incorporated by reference into the registrant’s registration statements on Form F-3 (File nos. 333-251055, 333-245703 and 333-251065) filed with the Securities and Exchange Commission on December 1, 2020, December 2, 2020 and December 2, 2020, respectively, and the registration statement on Form S-8 (File no. 333-235692) filed with the Securities and Exchange Commission on December 23, 2019.

Extension of the Option Agreement entered into between Liminal BioSciences Inc. and Kedrion S.p.A.

Liminal Biosciences Inc. (the “Company”) today announced that it has amended the Option Agreement it entered into with Kedrion S.p.A. on May 21, 2021 to extend the option exercise period under such Option Agreement from June 15, 2021 to June 22, 2021.